Pharma Mar (OTCMKTS:PHMMF) Short Interest Up 1,430.8% in July

Pharma Mar (OTCMKTS:PHMMF) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 199 shares, a growth of 1,430.8% from the July 15th total of 13 shares. Based on an average trading volume of 15 shares, the short-interest ratio is currently 13.3 days. Currently, 0.0% of the company’s shares are sold short.

Pharma Mar Price Performance

PHMMF stock remained flat at $87.58 during mid-day trading on Tuesday. Pharma Mar has a 12 month low of $77.41 and a 12 month high of $110.40. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. The stock’s fifty day moving average is $87.24 and its two-hundred day moving average is $93.68.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PHMMF. Chardan Capital upgraded shares of Pharma Mar to a “strong-buy” rating in a research report on Tuesday, June 9th. BTIG Research began coverage on shares of Pharma Mar in a research report on Thursday, April 23rd. They set a “buy” rating for the company. Finally, Zacks Research raised shares of Pharma Mar to a “hold” rating in a research note on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Buy”.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.